Summit Global Investments Takes $4.68 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Summit Global Investments acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 7,506 shares of the biopharmaceutical company’s stock, valued at approximately $4,680,000.

Several other large investors have also made changes to their positions in REGN. Orbimed Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $11,358,000. Lockheed Martin Investment Management Co. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $2,702,000. National Pension Service raised its stake in Regeneron Pharmaceuticals by 29.8% during the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after purchasing an additional 82,853 shares during the last quarter. AE Wealth Management LLC boosted its holdings in Regeneron Pharmaceuticals by 36.7% in the 4th quarter. AE Wealth Management LLC now owns 5,474 shares of the biopharmaceutical company’s stock valued at $4,226,000 after purchasing an additional 1,470 shares during the period. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $10,472,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN stock opened at $803.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The stock has a market cap of $82.73 billion, a price-to-earnings ratio of 19.86, a P/E/G ratio of 1.37 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a fifty day moving average of $675.79 and a 200-day moving average of $714.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period last year, the firm earned $12.81 EPS. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is expanding its oncology relationship with Biohaven through a clinical supply agreement to test Biohaven’s BHV-1530 alongside Regeneron’s Libtayo in patients with solid tumors. The combination could strengthen Regeneron’s oncology pipeline if clinical results are favorable. Biohaven-Regeneron Oncology Deal
• Positive Sentiment: Regeneron also entered a strategic research collaboration with Parabilis Medicines to develop antibody-Helicon conjugates. The agreement includes $125 million in upfront consideration and equity investment for Parabilis, with potential milestone payments of up to $2.2 billion plus royalties—highlighting Regeneron’s efforts to broaden its technology base and future pipeline. Parabilis Medicines-Regeneron Collaboration
• Neutral Sentiment: Coverage highlights Regeneron’s exposure to GLP-1-related growth opportunities beyond the leading weight-loss drug makers, although the article provides limited new company-specific financial information. GLP-1 Demand and Regeneron
• Neutral Sentiment: Director Kathryn Guarini sold $320,000 of REGN stock under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance, it is a limited indicator of management’s current outlook.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron concerning alleged disclosures about the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, and the continuing legal notices may keep investor attention focused on potential litigation costs, disclosure risks and weakness in the oncology program. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the sale, the director directly owned 603 shares of the company’s stock, valued at approximately $482,400. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have issued reports on REGN. Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Finally, TD Cowen raised their price objective on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $793.74.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.